- Home
- SPPL vs ASBP Comparison
SPPL vs ASBP Comparison
Compare SPPL & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPPL | ASBP |
|---|---|---|
| Founded | 2016 | 2021 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5M | 18.9M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | SPPL | ASBP |
|---|---|---|
| Price | $4.21 | $0.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.5K | ★ 68.8M |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,591,508.00 | $1,941.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.27 | N/A |
| 52 Week Low | $2.18 | $0.08 |
| 52 Week High | $16.80 | $15.80 |
Technical Indicators
Market Signals| Indicator | SPPL | ASBP |
|---|---|---|
| Relative Strength Index (RSI) | 47.10 | 27.78 |
| Support Level | $3.49 | $0.08 |
| Resistance Level | $4.75 | $0.11 |
| Average True Range (ATR) | 0.23 | 0.01 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 57.85 | 13.32 |
Price Performance
Historical ComparisonAbout SPPL SIMPPLE LTD.
Simpple Ltd delivers an ecosystem solution that combines Internet-of-Things devices, robotic solutions, and an integrated software system operating in unison to position buildings to be future-ready. The company operates through two primary segments: the sale, warranty, and maintenance of autonomous robotic cleaning equipment (Robots), and the sale of facilities management software. The majority of its revenue is generated from the Robots segment.
About ASBP Aspire Biopharma Holdings Inc.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.